Compare Cisco Systems Inc (CSCO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Cisco Systems (CSCO) trades at $119.25, down 1.7% over 24 hours, with a bullish technical signal from moving averages and recent AI-driven news boosting sentiment. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.06 exceeding the $1.03 estimate. Financials show solid profitability with a 64.33% gross margin and $10.18B net income for 2025, though valuation ratios like P/E of 39.03 appear elevated. Analyst consensus is bullish with a $130.38 price target, supported by 38 buy ratings.

Outlook remains positive due to AI cybersecurity demand and partnerships, but risks include high debt levels and competitive pressures. The stock offers growth potential from tech infrastructure trends, yet investors should monitor execution on AI initiatives and macroeconomic headwinds that could impact networking spending.

Regeneron (REGN) trades at $663.09, down slightly by 0.22% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability, with a net income margin of 29.65% and consistent earnings beats in recent quarters. Recent positive news includes FDA and EMA acceptance of its cemdisiran application for gMG and selection for an FDA pilot program to accelerate manufacturing reviews, highlighting operational momentum.

The outlook remains positive given analyst consensus with a $764.50 price target and no sell ratings, though risks include regulatory hurdles and competitive pressures in biotech. Earnings growth and pipeline advancements are key catalysts, but investors should weigh high RSI levels suggesting potential near-term overbought conditions against strong fundamental performance.